Enveric Biosciences (NASDAQ:ENVB) Stock Breaks Above 50 Day Moving Average – Here’s Why

Enveric Biosciences, Inc. (NASDAQ:ENVB) shares crossed above its 50 day moving average during trading on Tuesday. The stock has a 50 day moving average of $1.46 and traded as high as $1.51. Enveric Biosciences shares last traded at $1.50, with a volume of 43,268 shares changing hands.

Analysts Set New Price Targets

A number of brokerages have commented on ENVB. Wall Street Zen upgraded shares of Enveric Biosciences from a “sell” rating to a “hold” rating in a research note on Sunday, August 23rd. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Enveric Biosciences in a research report on Thursday, October 15th. One equities research analyst has rated the stock with a Sell rating. Based on data from MarketBeat, the company presently has an average rating of “Sell”.

Enveric Biosciences Stock Up 3.4%

The stock’s 50 day moving average is $1.46 and its two-hundred day moving average is $2.00. The company has a market capitalization of $6.72 million, a PE ratio of -0.12 and a beta of 1.23.

Enveric Biosciences (NASDAQ:ENVB) last issued its earnings results on Friday, August 14th. The company reported ($0.76) earnings per share (EPS) for the quarter.

Hedge Funds Weigh In On Enveric Biosciences

A hedge fund recently raised its position in Enveric Biosciences stock. StoneX Group Inc. increased its holdings in shares of Enveric Biosciences, Inc. (NASDAQ:ENVB) by 136.9% during the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 27,986 shares of the company’s stock after purchasing an additional 16,172 shares during the period. StoneX Group Inc. owned 0.63% of Enveric Biosciences worth $41,000 as of its most recent SEC filing. 13.82% of the stock is currently owned by institutional investors.

Enveric Biosciences Company Profile

Enveric Biosciences, Inc is a biotechnology company focused on discovering and developing novel small-molecule therapeutics for cancer and central nervous system disorders. The company’s research uses insights from cannabinoid science and psychedelic-inspired compounds to identify potential treatments for conditions with significant unmet medical needs.

Enveric has developed a portfolio of proprietary drug candidates and intellectual property, including programs aimed at mental health conditions such as depression and other neurological disorders, as well as therapies intended to address cancer-related symptoms and supportive-care needs.